Continuing Nivolumab After Progression Improves Survival in RCC
In this video we discuss the continuation of nivolumab after tumor progression in patients with advanced renal cell carcinoma in the CheckMate 025 trial.
The continuation of nivolumab after tumor progression in patients with advanced renal cell carcinoma in the CheckMate 025 trial was found to extend survival, according to data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, held earlier this month in Chicago (abstract 4509).
Median overall survival was 28.1 months for patients who continued to receive treatment vs 15 months for patients who stopped treatment at progression. In this video Saby George, MD, of the Roswell Park Cancer Institute in Buffalo, New York, discusses these results.
Hereditary Renal Tumor Syndromes and the Use of mTOR Inhibitors
A 47-year-old woman with a history of drug-resistant epilepsy during childhood presented to the emergency department with sudden dyspnea and chest pain. Upon admission, her oxygen saturation was 88%.
